FN1 and myasthenia gravis: Taking these results into account, we speculated that EDB-FN could be used as a diagnostic and noninvasive therapeutic drug delivery target candidate in MG, and we performed conventional in vitro and in vivo experiments for validation, including orthotopic xenograft animal model experiments.